Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.
Damond
Florence
F
Matheron
Sophie
S
Peytavin
Gilles
G
Campa
Pauline
P
Taieb
Audrey
A
Collin
Gilles
G
Delaunay
Christophe
C
Chêne
Geneviève
G
Brun-Vézinet
Françoise
F
Descamps
Diane
D
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use*; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005602:France; D005838:Genotype; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D054303:HIV Reverse Transcriptase; D015498:HIV-2 / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D009154:Mutation; D063065:Organophosphonates / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D012194:RNA-Directed DNA Polymerase / Q000235:genetics*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000068698:Tenofovir; D013997:Time Factors
D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; C072416:reverse transcriptase, Human immunodeficiency virus 2; D054303:HIV Reverse Transcriptase; D012194:RNA-Directed DNA Polymerase; D000225:Adenine